Targets › HMG1
1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 1; Genitourinary, Infectious disease, Other; next expected readout Mar 2027.
Multifunctional redox sensitive protein with various roles in different cellular compartments. In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. (UniProt, P09429)
Open in Phaseline: the race on HMG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | fosmanogepix GPI-anchored wall transfer protein 1 inhibitor | IPCS1, HMG1, FKS1 | Phase 3 | Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on Dialysis | Mar 2027 |
Candidemia (1) Invasive Mold Infections (1) Healthy Adult Participants (1) End Stage Renal Disease on Dialysis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.